Literature DB >> 18338167

PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective.

Dmitri Soloviev1, Alberto Fini, Franca Chierichetti, Adil Al-Nahhas, Domenico Rubello.   

Abstract

PURPOSE: In the present study, the potential clinical role of 11C-acetate PET mainly in the differential diagnosis, in the staging and in the follow-up of prostate cancer patients is reported.
METHODS: Each of the above points has been accurately investigated by studying the specific biochemical and radiobiochemical behaviour of this positron emitter compound. RESULTS AND
CONCLUSION: The imaging quality of 11C-acetate PET and its unique mechanisms of cellular uptake, make such radiotracer a powerful tool in evaluating all the steps of the prostatic cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18338167     DOI: 10.1007/s00259-007-0662-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  30 in total

Review 1.  Increased lipogenesis in cancer cells: new players, novel targets.

Authors:  Johannes V Swinnen; Koen Brusselmans; Guido Verhoeven
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2006-07       Impact factor: 4.294

2.  Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway.

Authors:  H Heemers; B Maes; F Foufelle; W Heyns; G Verhoeven; J V Swinnen
Journal:  Mol Endocrinol       Date:  2001-10

3.  Preferential labeling of glial and meningial brain tumors with [2-(14)C]acetate.

Authors:  G A Dienel; D Popp; P D Drew; K Ball; A Krisht; N F Cruz
Journal:  J Nucl Med       Date:  2001-08       Impact factor: 10.057

4.  Molecular characterization of human acetyl-CoA synthetase, an enzyme regulated by sterol regulatory element-binding proteins.

Authors:  A Luong; V C Hannah; M S Brown; J L Goldstein
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

5.  Radiation dose estimates in humans for (11)C-acetate whole-body PET.

Authors:  Marc A Seltzer; Shamim A Jahan; Richard Sparks; David B Stout; Nagichettiar Satyamurthy; Magnus Dahlbom; Michael E Phelps; Jorge R Barrio
Journal:  J Nucl Med       Date:  2004-07       Impact factor: 10.057

6.  Liver and adipose tissue contributions to newly formed fatty acids in an ascites tumor.

Authors:  M Ookhtens; R Kannan; I Lyon; N Baker
Journal:  Am J Physiol       Date:  1984-07

7.  Preferential utilization of acetate by astrocytes is attributable to transport.

Authors:  R A Waniewski; D L Martin
Journal:  J Neurosci       Date:  1998-07-15       Impact factor: 6.167

8.  Interaction of androgens and prolactin on prostatic enzymes of the pyruvate-malate cycle involved in lipogenesis in castrated mature monkey, Macaca radiata.

Authors:  J Arunakaran; K Balasubramanian; N Srinivasan; M M Aruldhas; P Govindarajulu
Journal:  Cytobios       Date:  1992

9.  Carbon-11-acetate PET imaging in renal disease.

Authors:  P Shreve; P C Chiao; H D Humes; M Schwaiger; M D Gross
Journal:  J Nucl Med       Date:  1995-09       Impact factor: 10.057

Review 10.  The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots.

Authors:  Leslie C Costello; Renty B Franklin
Journal:  Mol Cancer       Date:  2006-05-15       Impact factor: 27.401

View more
  13 in total

Review 1.  Beyond haematuria in uro oncology: imaging biomarkers lag behind needs.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01       Impact factor: 9.236

Review 2.  Molecular imaging of prostate cancer: PET radiotracers.

Authors:  Hossein Jadvar
Journal:  AJR Am J Roentgenol       Date:  2012-08       Impact factor: 3.959

Review 3.  Application of metabolic PET imaging in radiation oncology.

Authors:  Aizhi Zhu; David M Marcus; Hui-Kuo G Shu; Hyunsuk Shim
Journal:  Radiat Res       Date:  2012-02-17       Impact factor: 2.841

4.  Pharmacokinetics, metabolism, biodistribution, radiation dosimetry, and toxicology of (18)F-fluoroacetate ((18)F-FACE) in non-human primates.

Authors:  Ryuichi Nishii; William Tong; Richard Wendt; Suren Soghomonyan; Uday Mukhopadhyay; Julius Balatoni; Osama Mawlawi; Luc Bidaut; Peggy Tinkey; Agatha Borne; Mian Alauddin; Carlos Gonzalez-Lepera; Bijun Yang; Juri G Gelovani
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

Review 5.  Functional imaging for prostate cancer: therapeutic implications.

Authors:  Carina Mari Aparici; Youngho Seo
Journal:  Semin Nucl Med       Date:  2012-09       Impact factor: 4.446

6.  [(18)F]Fluoroacetate is not a functional analogue of [(11)C]acetate in normal physiology.

Authors:  Orjan Lindhe; Aijun Sun; Johan Ulin; Obaidur Rahman; Bengt Långström; Jens Sörensen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-22       Impact factor: 9.236

Review 7.  Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer.

Authors:  Kirsten Bouchelouche; Jacek Capala; Peter Oehr
Journal:  Curr Opin Oncol       Date:  2009-09       Impact factor: 3.645

8.  Imaging with non-FDG PET tracers: outlook for current clinical applications.

Authors:  Egesta Lopci; Cristina Nanni; Paolo Castellucci; Gian Carlo Montini; Vincenzo Allegri; Domenico Rubello; Franca Chierichetti; Valentina Ambrosini; Stefano Fanti
Journal:  Insights Imaging       Date:  2010-09-23

9.  Kinetic analysis of dynamic (11)C-acetate PET/CT imaging as a potential method for differentiation of hepatocellular carcinoma and benign liver lesions.

Authors:  Li Huo; Jinxia Guo; Yonghong Dang; Jinqiao Lv; Youjing Zheng; Fang Li; Qingguo Xie; Xiaoyuan Chen
Journal:  Theranostics       Date:  2015-01-21       Impact factor: 11.556

10.  Characterization of hepatic tumors using [11C]metomidate through positron emission tomography: comparison with [11C]acetate.

Authors:  Anne Roivainen; Alexandru Naum; Heikki Nuutinen; Rauli Leino; Heimo Nurmi; Kjell Någren; Riitta Parkkola; Johanna Virtanen; Markku Kallajoki; Harry Kujari; Jari Ovaska; Peter Roberts; Marko Seppänen
Journal:  EJNMMI Res       Date:  2013-02-27       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.